Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Diagnostics as the first line of defense in global health security

Nature Biotechnology volume 32, pages 513–514 (2014)Cite this article

Subjects

The creation of the Global Health Security Agenda is a key step in the goal of combatting outbreaks in an increasingly interconnected world. It is too bad that the initiative is so woefully underfunded.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Mark Kessel is chairman of the Foundation for Innovative New Diagnostics (FIND), of counsel to Shearman and Sterling LLP and a founding partner of Symphony Capital LLP, New York, NY, USA.,

    Mark Kessel

Authors
  1. Mark Kessel
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Mark Kessel.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kessel, M. Diagnostics as the first line of defense in global health security. Nat Biotechnol 32, 513–514 (2014). https://doi.org/10.1038/nbt.2930

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt.2930

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research